Abstract
What makes a peptide an epitope? This is a central question in immunology. The clear identification of precise molecular characteristics of epitopes would help define the basic mechanisms of self/non-self distinction and lead to a greater understanding of phenomena such as tolerance, autoimmunity, allergy, and tumor escape of immune surveillance. Importantly, clarifying the properties an epitope is paramount to the development of diagnostic and therapeutic vaccines. This review analyzes recent reports on experimentally identified B cell epitopes associated with multiple infectious disease pathologies, cancer, autoimmunity, hypertension, obesity, and allergy. It illustrates data that further support the notion that only a low level of sequence similarity to the host proteome is needed to modulate the B cell epitope-specific peptidome. Amino acid sequences that are unique to the antigen and are not shared with the host proteome are specifically targeted by the humoral immune response. Therefore, low-similarity peptides may be significant to the rational development of peptide-based clinical treatments in cancer, autoimmunity, infection, and allergy. Biologically, the lowsimilarity hypothesis further supports sequence uniqueness as the molecular signature of “ nonselfness ” in the currently ongoing self/non-self debate.
Keywords: Peptide, epitope-immunoglobulin interaction, self/nonself, sequence similarity, sequence uniqueness
Current Pharmaceutical Design
Title: “Self-Nonself” Peptides in the Design of Vaccines
Volume: 15 Issue: 28
Author(s): Darja Kanduc
Affiliation:
Keywords: Peptide, epitope-immunoglobulin interaction, self/nonself, sequence similarity, sequence uniqueness
Abstract: What makes a peptide an epitope? This is a central question in immunology. The clear identification of precise molecular characteristics of epitopes would help define the basic mechanisms of self/non-self distinction and lead to a greater understanding of phenomena such as tolerance, autoimmunity, allergy, and tumor escape of immune surveillance. Importantly, clarifying the properties an epitope is paramount to the development of diagnostic and therapeutic vaccines. This review analyzes recent reports on experimentally identified B cell epitopes associated with multiple infectious disease pathologies, cancer, autoimmunity, hypertension, obesity, and allergy. It illustrates data that further support the notion that only a low level of sequence similarity to the host proteome is needed to modulate the B cell epitope-specific peptidome. Amino acid sequences that are unique to the antigen and are not shared with the host proteome are specifically targeted by the humoral immune response. Therefore, low-similarity peptides may be significant to the rational development of peptide-based clinical treatments in cancer, autoimmunity, infection, and allergy. Biologically, the lowsimilarity hypothesis further supports sequence uniqueness as the molecular signature of “ nonselfness ” in the currently ongoing self/non-self debate.
Export Options
About this article
Cite this article as:
Kanduc Darja, “Self-Nonself” Peptides in the Design of Vaccines, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105135
DOI https://dx.doi.org/10.2174/138161209789105135 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Poly(ADP-Ribose) Polymerase Inhibitors
Current Medicinal Chemistry New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Current Cancer Drug Targets Spots, Blots, Peaks and Chips: Proteomic Approaches in Autoimmune Diseases
Current Pharmaceutical Design Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Monoamine Involvement in the Antidepressant-Like Effect of β-Caryophyllene
CNS & Neurological Disorders - Drug Targets Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) HLA-DR: Molecular Insights and Vaccine Design
Current Pharmaceutical Design Neuronal Semaphorins Regulate a Primary Immune Response
Current Neurovascular Research Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism The Molecular Basis of Th2 Development
Current Immunology Reviews (Discontinued) Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in Neuro-Endocrine-Immune Interactions in the Pathophysiology of Rheumatoid Arthritis
Current Rheumatology Reviews Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design